

OBIL/BSE/13/2018-2019

14<sup>th</sup> August, 2018

To,  
The Corporate Relations Department  
The Bombay Stock Exchange Ltd,  
P J Towers, 1<sup>st</sup> Floor,  
Dalal Street,  
Mumbai – 400 001

Dear Sir/Madam,

Ref: Scrip Code: 538019

ISIN: INE732P01018

**Sub:** Submission of Standalone Unaudited Financial Results for the quarter ended 30<sup>th</sup> June, 2018.

This is to inform you that the meeting of the Board of Directors was held today, 14<sup>th</sup> August, 2018 inter alia, to consider and approve the Unaudited (limited reviewed) Financial Results for the quarter ended 30.06.2018.

In this regard, the following documents are enclosed herewith:

- Standalone Unaudited Financial Results for the quarter ended 30.06.2018 - Regulation 33 - Annexure I of SEBI (LODR) Regulations, 2015.
- Limited review report signed by the Statutory Auditor

The meeting commenced at 10:00 a.m. and concluded at 12:00 p.m.


Kindly update the above in your records.

Thanking You.

For Oceanaa Biotek Industries Limited



Xavier Jeyaraj  
Managing Director  
Encl: As above



**M/S. OCEANAA BIOTEK INDUSTRIES LIMITED**  
CIN: L15549TN2005PLC057919  
No.4B-1 Eastern Portion, 4th Floor, Centre Point Appointment,  
Sadhullah Street, T Nagar, Chennai 600 017

**Statement of Standalone Unaudited Financial Results for the quarter ended 30.06.2018**

**Part I** in lakhs except earnings per share and share information/data  
Quarter ended 30/06/2018

S.No	Particulars	Three Months Ended			Year Ended
		30th June' 2018	31st March' 2018	30th June' 2017	31st March' 2018
		Unaudited	Audited	Unaudited	Audited
	<b>Revenue from Operations</b>				
I.	(a) Income from Operations	1,101.91	2,170.94	940.57	6,044.53
II.	(b) Other Income (net)	0.10	0.10	4.06	7.50
III.	<b>Total Revenue</b>	<b>1,102.01</b>	<b>2,171.04</b>	<b>944.63</b>	<b>6,052.03</b>
IV.	<b>Expenses</b>				
	a. Purchase of stock-in-trade	583.70	911.05	401.38	3,127.87
	b.Changes in inventory of finished goods	117.94	-329.86	246.39	-150.48
	c. Employee benefit expenses	62.95	91.86	33.45	213.80
	d. Finance costs	3.11	2.89	0.92	8.43
	e. Depreciation and amortisation expenses	78.89	98.20	80.36	346.41
	f. Other expenses	181.84	438.83	184.14	814.83
	<b>Total Expenses</b>	<b>1,028.42</b>	<b>1,212.98</b>	<b>946.64</b>	<b>4,360.87</b>
V.	<b>Profit/(Loss) before exceptional and extraordinary items and tax (I</b>	<b>73.59</b>	<b>958.06</b>	<b>-2.01</b>	<b>1,691.16</b>
VI.	Exceptional Items	-	-	-	-
VII.	<b>Profit / (Loss) before extraordinary items and tax (V-VI)</b>	<b>73.59</b>	<b>958.06</b>	<b>-2.01</b>	<b>1,691.16</b>
VIII.	Extraordinary Item	-	-	-	-
IX.	<b>Profit before tax (VII-VIII)</b>	<b>73.59</b>	<b>958.06</b>	<b>-2.01</b>	<b>1,691.16</b>
X.	Tax expense				
1	Current tax	21.22	432.55	38.50	548.05
2	Deferred tax	-55.35	28.27	7.06	49.44
XI.	<b>Profit / (Loss) for the period from continuing operations (VII-VIII</b>	<b>107.72</b>	<b>497.24</b>	<b>-47.56</b>	<b>1,093.67</b>
XII.	Other Comprehensive Income				
XIII.	Profit / (Loss) from discontinuing operations	-	-	-	-
XIV.	Tax expenses of discontinuing operations	-	-	-	-
XV.	<b>Profit / (Loss) from discontinuing operations (after tax) (XII-XIII)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
XVI.	<b>Profit (Loss) for the period (XI+XIV)</b>	<b>107.72</b>	<b>497.24</b>	<b>-47.56</b>	<b>1,093.67</b>
XVII.	<b>Earnings per equity Share</b>				
	(1) Basic	0.79	3.67	-0.35	8.06
	(2) Diluted	0.79	3.67	-0.35	8.06
	See accompanying notes to the financial statements.				


**Notes:**

- 1 The Unaudited Financial results were reviewed by the Audit Committee and taken on record by the Board of directors at their meeting held on 14th August, 2018
- 2 Figures of the previous period/year are reclassified /regrouped or rearranged wherever necessary to make it comparable.
- 3 There are no separate reportable segments for the three months ended as per Accounting Standard 17 on segment reporting notified under the Companies (Accounting Standard) Rules 2015.
- 4 There were no Investors' Complaints pending/received during the period.
- 5 All the financial numbers presented above are prepared as per the IND AS.

For and On Behalf of Board of Directors

Place: Chennai  
Date : 14/08/2018

Thomas Xavier Jeyaraj  
Managing Director  
DIN:06896574





### Limited Review Report

**Review Report to**  
**The Board of Directors**  
**Oceanaa Biotech Industries Limited**

We have reviewed the accompanying statement of unaudited financial results ("The Statement") of **Oceanaa Biotech Industries Limited ("the Company")** for the Quarter ended on **30<sup>th</sup> June, 2018** prepared by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 read with SEBI circular no. CIR/CFD/FAC/62/2016 dated 5<sup>th</sup> July 2016. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ committee of Board of Directors of the Issuer. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "*Review of Financial Information Performed by the Independent Auditor of the Entity*" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Issuer's personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards (IND AS) as specified under section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2015 and other recognized accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI circular no. CIR/CFD/FAC/62/2016 dated July, 05 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Elangovan & Co.**  
**Chartered Accountants**  
**Firm Regn. No. 0069905**

  
**S. Sathish Kumar**

**Partner**

**M.No: 226384**

**Place: Chennai**

**Date: 14/08/2018**



Dated: 14<sup>th</sup> August, 2018


**DECLARATION**

M/s Elangovan & Co., Chartered Accountants, Statutory Auditors of the Company have given an unmodified opinion with respect to the Standalone un-audited financial results for the quarter ended 30<sup>th</sup> June, 2018.


This declaration is submitted in compliance with Regulation 33 (3) (d) of the SEBI (Listing Obligations and Disclosure Requirements) (Amendments) Regulation, 2016, as issued by SEBI vide Notification No.SEBI/LAD-NRO/GN/2016-17/001 dated May, 25, 2016.

For Oceanaa Biotech Industries Limited

Xavier Jeyaraj  
Managing Director  
Place: Chennai



For Elangovan & Co.,  
Chartered Accountants  
FRN: 006990S

  
CA S Sathish Kumar  
Partner  
M No.: 226384

To  
The Board of Directors,  
No.4B-1 Eastern Portion, 4th Floor, Centre Point Appointment,  
Sadhullah Street, T Nagār, Chennai 600 017,  
Tamil Nadu


Dear Sir/Madam,


We hereby confirm the following in respect of the unaudited financial statements for the quarter ended on 30<sup>th</sup> June, 2018 being presented before the Board at the meeting to be held on 14<sup>th</sup> August, 2018.

- (1) That to the best of our knowledge, the financial results do not contain any false or misleading statement of figures.
- (2) That to the best of our knowledge, the financial results do not omit any material fact which may make the statements or figures contained therein misleading.

Yours sincerely

Place: Chennai  
Date: 14.08.2018



  
Xavier Jeyaraj  
Managing Director  
DIN: 06896574